

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 16, 2020 (the “**Prospectus**”) issued by Kangji Medical Holdings Limited (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to sell, acquire, purchase or subscribe for any securities. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.



Kangji Medical Holdings Limited
康基医疗控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9997)

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

FULL EXERCISE OF OVER-ALLOTMENT OPTION

The Company announces that on June 30, 2020, the Over-allotment Option described in the Prospectus has been fully exercised by the Joint Global Coordinators, on behalf of the International Underwriters, in respect of an aggregate of 33,809,500 Shares, representing approximately 15% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), to cover over-allocations in the Global Offering. The Sale Shares will be sold by the Selling Shareholder at HK\$13.88 per Sale Share (exclusive of SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

A further announcement will be made by the Company after the end of the stabilization period.

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that on June 30, 2020, the Over-allotment Option described in the Prospectus has been fully exercised by the Joint Global Coordinators, on behalf of the International Underwriters, in respect of an aggregate of 33,809,500 Shares, representing approximately 15% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), to cover over-allocations in the Global Offering.

The Sale Shares will be sold by the Selling Shareholder at HK\$13.88 per Sale Share (exclusive of SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering. The Sale Shares will be used to facilitate the return of 33,809,500 borrowed Shares to Fortune Spring ZM B Limited, which were used to cover over-allocations of Shares in the International Offering.

APPROVAL OF LISTING

Approval for the listing of and permission to deal in the Sale Shares has already been granted by the Listing Committee of the Stock Exchange and the Sale Shares are existing Shares.

SHAREHOLDING STRUCTURE OF THE COMPANY UPON THE FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The shareholding structure of the Company immediately before and immediately after the completion of the full exercise of the Over-allotment Option is as follows:

Shareholders	Immediately before the completion of full exercise of the Over-allotment Option		Immediately after the completion of full exercise of the Over-allotment Option	
	Number of Shares	Approximate percentage of the Company's issued share capital	Number of Shares	Approximate percentage of the Company's issued share capital
Fortune Spring ZM B Limited*	408,500,000	32.62%	408,500,000	32.62%
Fortune Spring YG B Limited	231,500,000	18.49%	231,500,000	18.49%
Keyhole Holding Limited	250,000,000	19.96%	216,190,500	17.26%
LYFE Capital Fund, L.P.	65,780,000	5.25%	65,780,000	5.25%
LYFE Capital Fund-A, L.P.	10,970,000	0.88%	10,970,000	0.88%
Axiom Asia IV, L.P.	20,460,000	1.63%	20,460,000	1.63%
ARDIAN DIRECT ASIA III L.P.	12,790,000	1.02%	12,790,000	1.02%
ESOP Trust	26,810,000	2.14%	26,810,000	2.14%
Other public Shareholders	225,397,500	18.00%	259,207,000	20.70%
Total	1,252,207,500	100.00%	1,252,207,500	100.00%

* Inclusive of the Shares borrowed and to be returned by the Stabilizing Manager.

The Selling Shareholder will receive the net proceeds of approximately HK\$454.7 million (after deduction of proportional underwriting commissions and fees payable by the Selling Shareholder) from the sale of the Sale Shares pursuant to the full exercise of the Over-allotment Option. The Company will not receive any proceeds in respect of the sale of the Sale Shares.

PUBLIC FLOAT

Immediately after the full exercise of the Over-allotment Option, the Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules.

The Company will make a further announcement after the end of the stabilization period in connection with the Global Offering pursuant to Section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

By order of the Board
KANGJI MEDICAL HOLDINGS LIMITED
ZHONG Ming
Chairman

Hong Kong, June 30, 2020

As at the date of this announcement, the board of Directors of the Company comprises Mr. ZHONG Ming and Ms. SHENTU Yinguang as executive Directors; Ms. CAI Li and Mr. CHEN Gang as non-executive Directors; and Mr. JIANG Feng, Mr. GUO Jian and Mr. CHEN Weibo as independent non-executive Directors.